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Background. Growth retardation of chronic renal failure is
associated with alterations in the growth plate suggestive of a
disturbed chondrocyte maturation process and abnormal vascu-
lar invasion at the chondro-osseous interphase. Chondromod-
ulin I (ChM-I) is a potent cartilage-specific angiostatic factor.
Its pattern of expression in the uremic rat growth plate is un-
known. Persistence of ChM-I synthesis and/or imbalance be-
tween ChM-I and vascular endothelial growth factor (VEGF)
expressions might play a role in the alterations of uremic growth
plate.
Methods. Growth cartilage ChM-I expression was investi-
gated by immunohistochemistry, in situ hybridization, and re-
verse transcription-polymerase chain reaction (RT-PCR) in
growth-retarded young uremic rats (UREM), control rats, fed
ad libitum (SAL) or pair-fed with the UREM group (SPF), and
uremic rats treated with growth hormone (UREM-GH). VEGF
expression was analyzed by immunohistochemistry.
Results. ChM-I and ChM-I mRNA were confined to the pro-
liferative and early hypertrophic zones of growth cartilage. A
similar number of chondrocytes per column was positive for
ChM-I in the 4 groups. In accordance with the elongation of the
hypertrophic stratum in uremia, the distance (X±SEM, lm) be-
tween the extracellular ChM-I signal and the metaphyseal end
of growth cartilage was higher (P < 0.003) in UREM (236 ±
40) and UREM-GH (297 ± 17) than in SAL (92 ± 7) and SPF
(113 ± 6). No differences in ChM-I expression were appreci-
ated by RT-PCR. Similar VEGF positivity was observed in the
hypertrophic chondrocytes of all groups.
Conclusion. In experimental uremia, expansion of growth
cartilage does not result from increased or persistent expression
of ChM-I or from reduced VEGF expression at the cartilage-
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metaphyseal bone interphase. GH treatment does not modify
ChM-I and VEGF expressions.
Growth retardation is a major manifestation of chronic
renal failure in the pediatric age [1–3]. Several lines of
evidence indicate that renal failure causes peripheral re-
sistance to growth hormone action as a result not only
of the decreased renal function itself but also of the as-
sociated malnutrition [4–14]. However, the pathogenetic
mechanism of growth impairment in chronic renal fail-
ure remains to be determined. To clarify it, the study of
growth plate in the uremic rat model has progressively
gained in interest over the last years because it is the or-
gan where longitudinal growth takes place and it is hardly
available in children [15–17].
Growth failure induced by uremia is associated with
marked changes in the morphology of the growth plate.
Findings from our laboratory [18, 19] and others [20] have
shown that the tibial growth cartilage height of severely
uremic rats is much greater than that of control rats with
normal glomerular filtration rate (GFR), either fed ad li-
bitum or pair-fed with the subtotally nephrectomized ani-
mals. This indicates that this finding cannot be attributed
to the malnutrition associated to chronic renal failure.
Likewise, it was not observed in rats with metabolic acido-
sis, a metabolic disorder frequently found in renal failure,
and normal renal function [21]. Expansion of the chon-
drocyte columns in the growth plate of uremic rats results
from marked elongation of the hypertrophic zone and, as
inferred from a detailed histomorphometric analysis [19],
is related to alterations in the kinetics of chondrocytes
and an imbalance between cartilage formation and its re-
placement by bone. Increased hypertrophic zone height,
reduced size of the chondrocytes adjacent to the meta-
physeal bone, reduced expression of type X collagen, and
irregular cartilage-bone interphase all suggest a disturbed
maturation process of the growth cartilage cells of uremic
rats [19, 22, 23].
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Chondromodulin I (ChM-I) is a 25-kD glycoprotein
initially isolated from fetal bovine epiphyseal cartilage
[24]. ChM-I is specific of cartilage, stimulates the growth
of chondrocytes [24, 25], and inhibits endothelial cell
growth [26]. ChM-I is a potent antiangiogenic factor ex-
pressed in the avascular zone of cartilage in developing
bone of mammalian and avian embryos, but absent in
calcifying cartilage [27–32].
Formation of new capillary sprouts is a key and early
step required for replacement of chondrocytes by osseous
cells at the growth cartilage-primary spongy bone junc-
tion of the long bones [33, 34]. Because of the poten-
tial role of ChM-I as important regulator of angiogenesis
and the above-described findings indicative of disturbed
chondrocyte maturation at the growth plate, it is tempt-
ing to hypothesize that, in uremia, persistent synthesis of
ChM-I by the hypertrophic chondrocytes might lead to
inhibition of vessel arrival and the ensuing expansion of
growth cartilage. This might be important to understand
the changes induced by chronic renal failure in the growth
plate dynamics, and to provide some insight on the un-
derlying mechanism of growth retardation in this disease.
Similarly, the beneficial effect of growth hormone (GH)
administration on growth [35–37] might bring about sig-
nificant changes in the pattern of expression of ChM-1 in
the growth cartilage of uremic rats.
METHODS
Experimental protocol
Female Sprague-Dawley rats aged 30 ± 2 days and
weighing 100 ± 5 g were obtained from the breeding area
of the animal facility building of the University of Oviedo.
Rats were housed in individual cages and maintained at
an environmental temperature of 22◦C and a 12-hour
light-dark cycle. After 3 days of acclimation to the exper-
imentation area, the animals were classified in the follow-
ing groups of 10 individuals each: rats with chronic renal
failure induced by 5/6 nephrectomy, untreated (UREM)
or treated with GH (UREM-GH); normal renal function,
sham-operated rats, either fed ad libitum (SAL) or pair-
fed with the uremic group (SPF). All animals had free
access to tap water and received standard rat chow with
a protein content of 17.2% (A04; Panlab, Barcelona,
Spain).
Subtotal nephrectomy or sham operation was per-
formed in two stages on days 0 and 4 of the protocol as
formerly described [17]. From day 4 on, animals and food
were weighed daily using an electronic balance (Ohaus
GT 2100; Florham Park, NJ, USA). Between days 11
and 17, animals were treated with 3.3 mg/kg/day (10 IU/
kg/day) of recombinant human GH (Norditropin, Novo
Nordisk Pharma, Madrid, Spain) injected intraperi-
toneally at approximately 9 a.m. and 5 p.m. Rats were
sacrificed under anesthesia on day 18 of the protocol.
Two days before sacrifice each animal received 20 mg/kg
of calcein (Sigma, St. Louis, MO, USA) by intraperitoneal
route.
Samples
Samples were collected at sacrifice. Serum samples
were stored at −20◦C until measurement of urea nitrogen
(SUN) and creatinine with a Kodak Ektachem DT60
analyzer (Rochester, NY). Tibias were removed and pro-
cessed as follows. Immediately after sacrifice, the prox-
imal end of the tibiae, including the growth plate, was
dissected. Tibias from four animals randomly chosen per
group were removed, kept in liquid nitrogen, and stored
at −80◦C for further RNA extraction. From the remain-
ing six animals per group, the right tibia was fixed in 40%
ethanol, and the left one in 4% neutral formalin, at 4◦C.
Then, both tibias were dehydrated in graded solutions of
ethanol and embedded in methylmethacrylate (MMA)
[38] for further histomorphometric, immunohistochemi-
cal, and in situ hybridization studies.
Growth and nutrition
Weight gained between days 11 and 18, the period of
GH treatment, was calculated. Longitudinal growth rate
was measured in 10-lm thick frontal sections of prox-
imal end of tibias obtained using a rotary microtome
(HM355S; Microm, Barcelona, Spain) fitted with tung-
sten carbide blades. Sections were examined under an
Olympus incident light fluorescence microscope (Olym-
pus BX41; Barcelona, Spain) coupled to a digital camera
(Olympus DP11, Olympus Optical Espan˜a, Barcelona,
Spain) to detect calcein label. Images were captured and
the distance between the chondro-osseous junction and
the calcein label was measured using an image analy-
sis system (Scion Image; Scion Corporation, Frederick,
MD, USA). The average value of these measurements
divided by 2 (days) was considered as the daily longitudi-
nal bone growth rate in each animal. Food efficiency was
calculated as the ratio between weight gained and food
consumed (g/g) by each animal between days 11 and 18
of the protocol.
Morphometric analysis of growth plate
Heights of growth cartilage and its hypertrophic zone,
as well as height and area of the three most distal hy-
perthrophic chondrocytes, were measured in 5-lm thick
sections stained with alzian blue and safranine at 20 loca-
tions on each section, using the above mentioned image
analysis system.
Immunohistochemical analysis for ChM-I and vascular
endothelial growth factor (VEGF)
Immunohistochemical staining for ChM-I or VEGF
was performed in ethanol- or formalin-fixed sections, re-
spectively. A 15-minute incubation in fresh 100% acetone
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was used to remove MMA from the tissue sections. After
hydration, the sections for ChM-I analysis were treated
with hyaluronidase [2 mg/mL, 1 h, 37◦C in phosphate-
buffered saline (PBS) at pH 5.0]. Then, all sections were
treated with 3% hydrogen peroxide and 25% goat serum
and incubated overnight (18 h) at 4◦C with 1/500 so-
lution of polyclonal anti-ChM-I antibody [32] or 6/100
polyclonal anti-VEGF (Neo Markers, Westinhouse, CA,
USA). After 30-minute incubation with antirabbit sec-
ondary conjugated antibody (EnVision +TM; Dako
Corporation, Carpinteria, CA, USA), the final reaction
product was revealed with 3–3′-diaminobenzidine (DAB)
(Sigma), (20 mg of DAB in 50 mL of 0.05 mol/L Tris-
hydrochloric buffer plus 50 lL of 30% hydrogen per-
oxide). Sections for VEGF immunohistochemistry were
counterstained with alzian blue.
Quantification of immunohistochemical staining
for ChM-I
Labeling index for ChM-I was calculated as the num-
ber of ChM-I–positive cells per column of chondrocytes.
To estimate the proximity of ChM-I signal to the meta-
physeal bone, the distance between the lower limit of the
extracellular signal for ChM-I and the chondro-osseous
junction was measured at 20 locations on each section.
To compare the signal of ChM-I observed in the present
experiment with that of rats of different ages, immunohis-
tochemical analysis of ChM-I expression was carried out
in tibias collected from 3-week and 12-week-old healthy
Sprague-Dawley rats.
In situ hybridization for ChM-I
The ChM-I antisense and sense DNA probes were
synthesized with EcoR1 and BamH1 linearized plasmid
pGEM 4Z, respectively, which contains a 499-base pair
fragment [32]. The plasmid was used as a template for syn-
thesis of antisense and sense digoxigenine-UTP-labeled
probes with T7 and SP6 polymerases. After hydration,
sections were treated with 300 lg/mL proteinase, fixed
in 4% paraformaldehyde, and washed in PBS containing
0.1% diethylpirocarbonate (DEPC) and 0.3% Triton
X-100. After incubation in 5 × standard sodium citrate
(SCC), prehybridization was performed for 1 hour at
42◦C. The prehybridization solution consisted of 50%
deionized fomamide, 4 × SCC, 50 × Denhardt’s solution,
5 g polyvinylpyrrolidone, 5 g bovine serum albumin
(BSA), and 250 lg/mL yeast tRNA. Hybridization solu-
tion was performed overnight at 42◦C. The hybridization
solution consisted of all components of the prehybridiza-
tion mixture in which the digoxigenine-UTP-labeled
probes were diluted and covered with plastic cover slips.
After washing in 2 × SSC at room temperature, and 2 ×
SSC and 0.1 × SSC at 42◦C, nonspecific binding was
blocked by 1 × blocking buffer (Blocking Reagent,
Boehringer Mannheim GmbH, Mannheim, Germany)
for 1 hour, and 20% goat serum in buffer A (1 mol/L
TrisHCl, 5 mol/L NaCl, pH 7.5) for 30 minutes. Slides
were placed in a moist chamber (ISO 20; Grant
Instruments, Cambridgeshire, UK) and were incubated
overnight with alkaline phosphatase–conjugated anti-
digoxigenine (1:1000; Boehringer Mannheim GmbH) in
buffer A at 4◦C. Sections were rinsed in buffer A and
then in buffer B (1 mol/L TrisHCl, 5 mol/L NaCl, MgCl2,
pH 9.5) for 10 minutes. Alkaline phosphatase was then
revealed with a substrate solution containing 0.16 mg/mL
5-bromo-4-chloro-3-indolylphosphatase (Sigma) and
0.33 mg/mL nitroblue tetrazolium (Sigma) in buffer B
for 15 minutes at room temperature. The enzymatic
reaction was stopped with a rinse in tap water. Sections
were dried at 37◦C and mounted with Vectamount
(Vector Laboratories, Burlingame, CA, USA).
Two parallel sections served as negative controls: one
section hybridized with a labeled-sense riboprobe, and a
second section incubated without adding any probe to the
hybridization mixture. No hybridization signal was found
in any of these negative controls. All solutions, when ap-
propriate, were prepared with 0.1% DEPC-treated wa-
ter. Sections were counterstained with nuclear red.
Reverse transcription-polymerase chain reaction
(RT-PCR) analysis
Total RNA from tibial growth plates stored at −80◦C
was extracted using acidic phenol extraction of guanidine
isothiocyanate lysate, according to the method of Chom-
czinsky and Sacchi [39], with minor modifications. The
quality of RNA was analyzed by agarose electrophoresis.
One pool of RNA was made for each group. The amount
of RNA was estimated by measuring the absorbancy at
260 nm.
PCR primers were deduced from rat ChM-I sequence.
RT-PCR was performed using the GeneAmp RNA
PCR Core Kit (Applied Biosystems, Foster City, CA,
USA) following the instructions of the manufacturer. In
brief, 1 lg of total RNA were reverse transcribed into
cDNA using random hexamers. The resulting cDNA was
amplified by PCR using specific primers pairs (ChM-
I F: 5′-AAGCAGTGCTCCCTCTACCA-3′ and R: 5′-
CTCTCTCCTTCCTGCTGGTG-3′) and 32 cycles of
94◦C for 30 seconds, 60◦C for 30 seconds, and 72◦C for
30 seconds after an initial 5-minute denaturation step at
94◦C. The amplified products (153 bp) were resolved on a
2% agarose gel and visualized by ethidium bromide stain-
ing and ultraviolet transillumination. As control, b-actin
was used following the same protocol that yielded a PCR
product of 294 bp. The PCR products were verified by
sequencing. Control reactions performed by omitting re-
verse transcriptase or template RNA showed no reaction
product. The optical densities of the PCR products were
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Table 1. Growth and nutrition in the four groups of animals
SAL (N = 10) SPF (N = 10) UREM (N = 10) UREM-GH (N = 10) P value
Weight gain Day 11 to 18 g 26.1 ± 1.6 21.2 ± 3.0d 18.7 ± 2.3a,d 32.9 ± 2.5 0.001
Food intake Day 11 to 18 g 121.8 ± 3.6 95.3 ± 6.8a 95.3 ± 6.8a 108.5 ± 5.1 0.001
Food efficiency day 11 to 18 g/g 0.21 ± 0.01 0.22 ± 0.03 0.20 ± 0.03 0.30 ± 0.02a,b,c 0.006
Longitudinal bone growth rate lm/day 143 ± 12 108 ± 10 60 ± 13a,b,d 132 ± 16 0.001
Abbreviations are: SAL, sham-operated rats fed ad libitum; SPF, sham-operated rats pair-fed with the UREM group; UREM, uremic rats; UREM-GH, uremic rats
treated with growth hormone. Data are given as mean ± SEM. Weight and food measurements are expressed from day 11 to 18 because this was the period of the
protocol corresponding to growth hormone treatment. Longitudinal growth rate was measured over the two days before sacrifice by calcein labeling.
aDifferent from SAL group; bdifferent from SPF group; cdifferent from UREM group; ddifferent from UREM-GH group.
Table 2. Morphologic features of proximal tibia growth plates in the four groups of animals
SAL (N = 6) SPF (N = 6) UREM (N = 6) UREM-GH (N = 6) P value
GP cartilage height lm 358 ± 14 351 ± 18 571 ± 37ab 657 ± 55ab 0.001
HZ height lm 160 ± 7 157 ± 7 360 ± 20ab 365 ± 20ab 0.001
HZ/GP height ratio lm/lm 0.45 ± 0.02 0.45 ± 0.02 0.60 ± 0.02ab 0.57 ± 0.04ab 0.001
Area of most distal chondrocytes lm2 477 ± 23 465 ± 32 360 ± 23abd 541 ± 21 0.003
Height of most distal chondrocytes lm 21 ± 1 20 ± 1 16 ± 2abd 22 ± 1 0.001
Abbreviations are: SAL, sham-operated rats fed ad libitum; SPF, sham-operated rats pair-fed with the UREM group; UREM, uremic rats; UREM-GH, uremic rats
treated with growth hormone; GP, growth plate; HZ, hypertrophic zone. Data are given as mean ± SEM.
aDifferent from SAL group; bdifferent from SPF group; cdifferent from UREM group; ddifferent from UREM-GH group.
analyzed by a computer program (Scion Corporation).
Results were normalized for the density of b-actin.
Statistical analysis
Values of each group are given as mean ± SEM. Com-
parisons among groups were performed by analysis of
variance (ANOVA) followed by the Newman-Keuls mul-
tiple range test or Kruskal Wallis test as appropriate. A
P value <0.05 was considered as indicative of significant
difference.
RESULTS
Renal function
Serum concentrations of urea nitrogen and creatinine
were higher (P < 0.001) in the UREM (50 ± 4 mg/dL and
0.9 ± 0.0 mg/dL) and UREM-GH (47 ± 3 mg/dL and 1.0 ±
0.0 mg/dL) groups than in SAL (12 ± 1 mg/dL and
0.5 ± 0.0 mg/dL) and SPF animals (13 ± 1 mg/dL and
0.3 ± 0.0 mg/dL). There were no differences between
the subtotally nephrectomized rats or between the sham-
operated groups.
Growth and nutrition
As shown in Table 1, UREM rats exhibited severe
growth retardation as demonstrated by less weight gain,
lower food consumption, reduced food efficiency, and de-
creased longitudinal bone growth rate than SAL group.
To a certain extent, the growth impairment was caused
by the depressed food intake because SPF animals also
grew worse than the SAL controls. However, particularly
in terms of longitudinal growth, poor growth of UREM
animals could not be exclusively attributed to the re-
duced food intake because their osseous front advance
was markedly lower than that of SPF rats. The bene-
ficial effect of GH treatment on growth became man-
ifest by increased weight gain and longitudinal growth
rate in UREM-GH compared with UREM animals. This
growth-promoting action was related to a better utiliza-
tion of consumed food.
Morphometry of growth plate
Heights of growth plate cartilage and its hypertrophic
zone were much higher in UREM than SAL rats
(Table 2). In addition, chondrocytes adjacent to the meta-
physeal bone were smaller in UREM animals. These
alterations were not found in the SPF group. GH adminis-
tration normalized chondrocyte size but not growth plate
cartilage height. An outstanding characteristic of growth
plate of UREM rats was the marked irregularity of the
chondro-osseous junction and the disturbed arrangement
of the chondrocyte columns.
Expression of ChM-I in the growth plate cartilage
A similar pattern of intracellular and extracellular im-
munohistochemical staining for ChM-I was observed in
the four groups of animals (Fig. 1). In the chondrocytes,
the protein was localized in the cytoplasma with a gran-
ular aspect. Within the growth plate, intracellular and
extracellular signals were confined to the transitional
zone between proliferative and hypertrophic chondro-
cytes. Neat positivity for ChM-I was also appreciable in
articular cartilage (data not shown). Quantitative assess-
ment of intracellular ChM-I signal revealed a small and
similar number of labeled cells per column in all groups:
1.5 ± 0.1 in SAL, 1.5 ± 0.3 in SPF, 2.1 ± 0.3 in UREM, and
1.6 ± 0.1 in UREM-GH. As the growth plate cartilages
were much higher in the chronic renal failure animals and
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the ChM-I signal did not extend beyond the early hyper-
trophic zone, the distance between the lower limit of the
extracellular ChM-I signal and the metaphyseal bone was
much greater (P < 0.003) in UREM (236 ± 40 lm) and
UREM-GH (297 ± 17 lm) than in SAL (92 ± 7 lm) and
SPF (113 ± 6 lm) groups.
The distribution of ChM-I mRNA as detected by in situ
hybridization was quite similar to that of immunohisto-
chemistry. Expression of ChM-I mRNA was mostly con-
fined to the transitional area between proliferative and
hypertrophic zones, no differences being found among
the four groups (Fig. 1). The specificity of the signal was
confirmed by its absence in the sections hybridized with
the sense probe, and without adding any probe.
Immunohistochemistry for ChM-I performed in
growth plate sections from healthy control rats served to
confirm that the small number of ChM-I–labeled chon-
drocytes was to a certain extent a function of age be-
cause ChM-I labeling index significantly decreased from
4.2 ± 0.7 cells/column in weaning rats of 3 weeks of age
to 0.3 ± 0.0 cells/column in 12-week-old adult rats. In-
terestingly, the distribution pattern of ChM-I expression
in the growth plate cartilage changed with age. In adult
individuals, ChM-I–positive cells were almost absent and
confined to the distal hypertrophic chondrocytes. By con-
trast, in 3-week-old rats, there was a strong extracellular
signal and a greater number of labeled cells in the resting,
proliferative, and early hypertrophic zones.
ChM-I mRNA expression was confirmed in all groups
by RT-PCR (Fig. 2).
RT-PCR yielded a 153-bp amplification product for the
ChM-I mRNA and a 294-bp product for b-actin mRNA.
No significant differences in the ChM-I/b-actin mRNA
ratios were observed among the four groups analyzed
(SAL: 0.85 ± 0.06; SPF: 1.13 ± 0.15; UREM: 0.68 ± 0.03;
UREM-GH: 0.85 ± 0.19).
Immunohistochemical analysis of VEGF expression
in growth plate
As shown in Figure 1, the VEGF immunohistochem-
ical signal was strong and no differences in the distribu-
tion pattern or intensity were apparent among the four
groups of rats. The VEGF signal was mostly intracellular
and localized within the cytoplasm of hypertrophic zone
chondrocytes. Staining was also found in the peripheral
rim of some chondrocyte lacunae. The majority of artic-
ular chondrocytes was also positive for VEGF (data not
shown).
DISCUSSION
The experimental protocol used in this study resulted
in sustainedly low growth rate in UREM rats as shown
by longitudinal bone growth rate, assessed by calcein la-
beling, significantly lower than that of SAL and SPF an-
imals. This indicates that the degree of induced chronic
renal failure was severe enough to produce a maintained
adverse effect on growth velocity. The finding that growth
rate of UREM rats was lower than that of SPF indi-
cates that the impairment of growth in those animals was
caused not only by the low food intake but also by a
uremia-derived specific effect. As demonstrated in for-
mer studies [35, 40, 41], treatment with high doses of
GH resulted in marked acceleration of growth velocity
even in the absence of a stimulatory effect on appetite.
This is concordant with the known anabolic effect of the
hormone.
Growth retardation of UREM rats was associated with
evident alterations in the histologic aspect of tibial growth
plate. Epiphyseal cartilage increased in height as a result
of an expansion of the hypertrophic zone, and the chon-
drocytes adjacent to the spongy metaphyseal bone were
reduced in size. These findings are in agreement with for-
mer studies of our group [18, 19] and others [20]. Other
authors have reported no modification [35, 40, 42], or
even decrease [43–45], of growth cartilage height in ure-
mic rats. The reasons for this lack of uniformity are not
clear, although the severity and duration of chronic renal
failure [46] and the calcium content of diet [47] have been
shown to exert an influence on growth plate morphology
in experimental uremia. In our study, the beneficial ef-
fect of GH treatment on growth was not accompanied by
significant additional changes in the height of the growth
cartilage and its hypertrophic zone but the aspect of most
distal chondrocytes normalized. It has been hypothesized
that expansion of chondrocyte columns in uremia results
from a disequilibrium between cartilage production at
the epiphyseal end of growth plate and bone apposition
at the metaphyseal end [19]. In uremic animals treated
with GH, the increased growth rate with persistence of
expanded growth plate cartilage indicates that GH stim-
ulates both bone formation rate and cartilage produc-
tion. On the other hand, the normalization of the size
of hypertrophic chondrocytes, as shown by the greater
area and height of the most distal growth cartilage cells
of UREM-GH rats in comparison with UREM group
(Table 2) and a more organized arrangement of chondro-
cyte columns suggest a beneficial action of GH treatment
on the process of chondrocyte maturation. Although a
detailed study on the modifications induced by GH treat-
ment on growth plate has not been published, adminis-
tration of GH to uremic rats has been shown to result in
increased expression of insulin-like growth factor I and its
mRNA in proliferative chondrocytes [40], as well as type
X collagen mRNA in hypertrophic chondrocytes [22, 23]
of growth plate.
The morphologic changes observed in the uremic
growth plate as well as former reports showing decreased
expression of markers of chondrocyte maturation, such
as type X collagen [22, 23] or parathyroid hormone/
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parathyroid hormone–related peptide receptor [22, 45],
in the growth plate of nephrectomized rats point to
a uremia-induced disorder of chondrocyte maturation.
Growth cartilage is avascular. It is tempting to speculate
that, in order to facilitate vascular and bone invasion, as
chondrocytes mature and approach the metaphyseal end
of cartilage column, genes encoding angiostatic factors
become suppressed, and genes encoding angiogenic fac-
tors become activated. The results of the study presented
here show that, in the four groups of animals, ChM-I
was expressed in the proliferative and early hypertrophic
strata, but not by the more mature chondrocytes located
closer to the metaphyseal bone front. On the contrary,
VEGF-positive cells were observed in the area of the hy-
pertrophic cartilage next to the primary spongiosa. This
agrees with the above hypothesis that in order to facilitate
the vascular invasion and, subsequently, the arrival of new
osseous tissue, the angiostatic activity of cartilage must
cease in the distal part adjacent to metaphyseal bone.
Our results do not support the assumption that de-
fective chondrocyte maturation might lead to persistent
expression of ChM-I and reduced VEGF synthesis and
explain the mechanism of growth plate elongation and
low bone formation rate of uremic individuals. There
were no significant modifications in the levels of ChM-
I and VEGF expression in the growth cartilage of uremic
rats in comparison with normal renal function rats ei-
ther fed ad libitum or pair-fed with the uremic animals.
It may be argued that, as the growth plate of uremic ani-
mals was markedly enlarged, the growth cartilage of these
animals produced substantially more ChM-I in absolute
terms than that of control animals. The increased amount
of ChM-I might exert a strong inhibition on the arrival
of the vascular invasion front. However, cartilage is avas-
cular and, consequently, ChM-I, a matrix peptide, should
exert its action by paracrine or autocrine mechanisms.
In our study, the distance between the lower limit of the
extracellular ChM-I signal and the metaphyseal bone was
greater in the uremic animals in consonance with the ex-
pansion of the hypertrophic growth cartilage zone. Thus,
a persistent antiangiogenic effect of ChM-I is not likely
to be responsible for the delayed vascular and bone inva-
sion. Likewise, the growth-promoting effect of GH treat-
ment was not associated with noticeable changes in the
expression of ChM-I or VEGF. This also questions the
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 1. Representative images showing immunohistochemical and in situ hybridization analysis performed in proximal tibial growth plates of SAL
(A1, A2, A3, A4, E1, E2), SPF (B1, B2, B3, E3), UREM (C1, C2, E4), and UREM-GH (D1, D2, E5) groups. Strong and similar in intensity and
distribution, extracellular immunohistochemical staining for ChM-I was observed in the intercellular matrix of proliferative and upper hyperthrophic
zones in all groups (A1, B1, C1, D1). Intracellular cytoplasmic signal was observed in few chondrocytes of these regions (A3). ChM-I mRNA was
strongly expressed, following a pattern of distribution similar to that of the protein (A2, A4, B2, C2, D2). Negative hybridization control with
sense probe is shown in B3. Most hyperthrophic chondrocytes showed an intense cytoplasmic immunohistochemical staining for VEGF without
differences among the groups (E1, E3, E4, E5). Calibration bar is 100 lm. Greater magnification of ChM-I, ChM-I mRNA, and VEGF signals are
shown in A3, A4, and E2. Abbreviations are: SAL, sham-operated rats fed ad libitum; SPF, sham-operated rats pair-fed with the UREM group;
UREM, uremic rats; UREM-GH, uremic rats treated with growth hormone.
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Fig. 2. Analysis of ChM-I mRNA expression by reverse transcription-
polymerase chain reaction (RT-PCR) in the four groups of rats. The
values of the ChM-I/b-actin ratio (mean ± SEM of three separate ex-
periments) were not significantly different among the four experimental
groups (A). Representative example of the RT-PCR amplified products
(B).
role of these peptides in the pathogenesis of growth re-
tardation in chronic renal failure.
The variable intensity and distribution of ChM-I ex-
pression found in our groups of rats of different ages
indicates that the role of this protein may change as the
individual becomes older, and it is also in agreement with
the progressive reduction of growth plate size with age.
Kitahara et al [48] found gradual decrease of ChM-I ex-
pression with age in the articular cartilage of rats. How-
ever, in their study, the intensity of ChM-I extracellular
signal in the epiphyseal cartilage remained unchanged.
Little is known on the function of ChM-I as regulator
of postnatal endochondral bone formation because most
investigations on ChM-I have been performed in cell cul-
tures or embryos [24, 26–31, 49]. Recently, it has been
shown that ChM-I knockout mice [50] exhibit normal
growth and fertility, but abnormal osseous remodeling in
the long run [51]. Therefore, it would be of high interest to
examine the pattern of expression of ChM-I in the bone
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of uremic animals with distinct forms of renal osteodys-
trophy and different concentrations of serum parathyroid
hormone.
CONCLUSION
The study presented here characterizes the pattern of
ChM-I expression in the growth cartilage of uremic rats.
Our results do not support a key role of ChM-I or VEGF
in the pathogenesis of growth plate alterations induced
by uremia, and in the mechanism responsible for growth
retardation in young individuals with chronic renal fail-
ure. Further studies are needed to clarify this issue, as
well as the function of ChM-I in the postnatal life.
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